OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books
Apr 16, 2020 • 21min
Journal Club: Unscheduled Hydration in Patients Receiving HEC
Our 1st Journal Club.
1. Read this: https://www.futuremedicine.com/doi/10.2217/fon-2018-0787
2. Ask how, or if, this would change practice.
3. Listen.
Apr 9, 2020 • 13min
Bevacizumab's Wild Ride For Metastatic Breast Cancer
First, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer.
Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1).
Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs...
E2100: https://www.nejm.org/doi/full/10.1056/nejmoa072113
Avado: https://www.ncbi.nlm.nih.gov/pubmed/20498403
Ribbon-1: https://www.ncbi.nlm.nih.gov/pubmed/21383283
Apr 2, 2020 • 16min
Caravaggio
Reviewing the lasted DOAC study in treating cancer-associated VTE: Caravaggio. We compare it the other major DOAC studies in this patient population. Caravaggio: https://www.nejm.org/doi/full/10.1056/NEJMoa1915103
Also, announcing our first journal club! This will be our 4/16 Pod. It is especially for an oncology APPE students missing out on an oncology experience, but all are welcome to participate. Journal Club link: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0787
Mar 27, 2020 • 19min
Bleomycin
The Foundations of OncoPharm series returns with a unique chemotherapy drug: bleomycin.
Also, Covid Thoughs (14:00).
Mar 19, 2020 • 18min
Recent Landmarks (CLEOPATRA, Keynote189)
Recent updated survival analyses for CLEOPATRA and Keynote-189 (6:45) require some historical context to truly see their impact. Finally, #AskOncoPharm returns (15:05) with a listener question about infusion rates when restarting daratumumab.
Mar 16, 2020 • 9min
*Covid19 And Chemo*
We all should do what we can to "flatten the curve" and that includes our patients on treatment. While there is no such thing as elective chemo, there are some practical ways we can minimize patients needing to come into our facilities.
Mar 12, 2020 • 8min
Viz-Aflibercept Pricing: A Case Study
Looking back at a 2012 NYT op-ed (https://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html) that led to a 50% price decrease in a biologic cancer medication.
Mar 5, 2020 • 29min
Pre - HOPA News Dunp
A plethora of #oncopharm updates!
Isatuximab is approved and neratinib gets another breast cancer indication (2:00)
Pembrolizumab with chemo for triple-negative breast cancer (8:50)
New EPOC updated survival analysis on FOLFOX+cetuximab in isolated liver metastatic colon cancer (15:00)
Precision medicine in pancreatic cancer (19:30)
Cladribine + rituximab for hairy cell leukemia (23:30)
Feb 27, 2020 • 19min
CYP2D6 & Tamoxifen Updates
Two recent publications add to our knowledge concerning the utility of CYP2D6 genotyping and tamoxifen.
TARGET-1: https://www.ncbi.nlm.nih.gov/pubmed/31821071
Tamoxifen D/C rates by 2D6 genotype: https://www.ncbi.nlm.nih.gov/pubmed/31800347
Feb 13, 2020 • 16min
CAR - NK
You've heard of CAR-T therapy, and now it's time to learn about CAR-NK cells.
Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa1910607
